25-year biopharma industry veteran joins the Company to drive further growth of its innovative high-performance cell engineering platform for use in commercial drug development Gaithersburg, Maryland – August 14, 2017: MaxCyte, a US-based global company dedicated to driving the acceleration of the
Gaithersburg, MD, January 16, 2017 – MaxCyte®, Inc., developer and supplier of cell engineering products and technologies to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announced today that Madhusudan V.
Preclinical research to focus on developing therapies based on MaxCyte’s proprietary CARMA platform – CARMA has potential for broad applicability against solid or liquid tumor indications Gaithersburg, MD, December 21, 2016 – MaxCyte®, Inc. today announces a strategic collaboration with
Biotech industry veteran to lead alliance-building efforts for MaxCyte’s proprietary CARMA platform Gaithersburg, Maryland – November 2, 2016 – MaxCyte, Inc., a developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and
Gaithersburg, MD, 29 September 2016 – MaxCyte®, Inc., an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and
